Racial and ethnic disparities in prostate cancer are well documented. Compared with White males, Black males have a 1.5 times higher chance of developing prostate cancer and 2.2 times higher likelihood of death resulting from the disease. Gaps in early diagnosis, treatment options and access, and survival rate remain for racial and ethnic underserved populations. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncological treatment for prostate cancer, thus resulting in delayed diagnosis and suboptimal clinical management, prognosis, and survival rate.
In this CME Outfitters podcast, expert faculty will review recent data and discuss the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with prostate cancer. This program will set the stage for intervention, empowering attendees to recognize and consider factors to improve prostate cancer treatment.
At the end of this CME/CE activity, participants should be able to understand and acknowledge the influence of bias, disparities, and inequities on prostate cancer care.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and dietitians, specializing in oncology, or involved in treating patients with prostate cancer
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Mitchell reports the following financial relationships:
Advisory Board: Corvus Pharmaceuticals, Inc.
Consultant: Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Genentech, Inc.; and SEMA4 OpCo, Inc.
Dr. Vince reports no financial relationships to disclose.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.